COVAXIN, India’s first indigenous COVID-19 vaccine manufactured by Bharat Biotech develop in collaboration with the Indian Council of Medical research(ICMR)-National Institute of Virology(NIV).

Medical name: COVAXINTM (BBV152)

Dose: one dose (0.5 ml), inactivated vaccine.

Solution: white translucent liquid

Therapeutic Indication: COVAXIN Indicated for active immunization against SARS-CoV-2 Virus infection for age >= 18 years Posology and method of administration: COVAXIN vaccination series 2 doses given 4 weeks apart.

Administration: The COVAXIN is injected directly into the deltoid muscle that is accessible in the upper arm.

Side effect of vaccine:
  • pain
  • Swelling
  • Redness and itching at the injection site body ache
  • Vomiting
  • fever
  • nausea
  • ashes
  • headache

Ingredient: COVAXIN mainly contain 6μg of whole-virion inactivated SARS-CoV-2 antigen(strain:NIV-2020-770), and the other inactive components such as 250ug aluminum hydroxide gel, 15μg TLR/8 agonist TM 2-phenoxyethanol, and phosphate, buffer saline up to 0.5ml.

Storage: The vaccine required no sub-zero storage and reconstitution requirement and available for use in multi-dose vials, stable at 2-8*c.

  • Hypersensitivity to any constituents of the vaccine,
  • pregnant and lactating mother
  • during fever or severe infection
  • Individuals below 18 years.